FindTrial
Sign In

Assessment of treatment outcome of Hypofractionated Radiotherapy using modern age radiotherapy technique with concurrent chemotherapy in Locally advanced cancers of Larynx and Hypopharynx

Prospective Study on Hypofractionated Intensity Modulated Radiation Therapy(using VMAT Technique) with Concurrent Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell Cancers

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/04/032672
Enrollment
44
Registered
2021-04-08
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C329- Malignant neoplasm of larynx, unspecified

Interventions

Intervention1: Hypofractionated Intensity Modulated Radiation Therapy (using VMAT Technique) with Concurrent Chemotherapy: Patients will receive concurrent chemo-radiation with 2 cycles of 3-weekly Ci

Sponsors

Chittaranjan National Cancer Institute
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Locally advanced, non-metastatic histopathology or cytology-proven, squamous cell carcinoma of Hypopharynx and Larynx (T3/T4a N0/N1/N2 M0) sent from multidisciplinary tumour board for CCRT. Age 20 years to 65 years. Eastern Cooperative Oncology Group (ECOG) performance status up to 2. Haemoglobin �10 gm%, white blood cell count �4000/mm3, platelet count �1 lakh/mm3 (initially or after correction by blood transfusion). Liver function test and kidney function test, both within normal limit. Baseline audiometry limited to mild sensory neural deficits.

Exclusion criteria

Exclusion criteria: Disease previously treated by radiotherapy, chemotherapy or surgery (other than biopsy and tracheostomy). Age 65 years. Patients having significant medical co-morbidities. Pregnancy or lactation. Evidence of distant metastasis. Patients unwilling to participate in the study or who do not give consent.

Design outcomes

Primary

MeasureTime frame
Evaluation of loco-regional response. Assessment of toxicity (Acute and Late). Timepoint: Evaluation of loco-regional response will be assessed at 3 months after completion of treatment. Assessment of toxicity (Acute and Late) during treatment and at 2 weeks, 4 weeks, 6 weeks, 3 months & 6 months after treatment.—

Secondary

MeasureTime frame
Assessment of disease-free survival. Timepoint: 2 years—

Countries

India

Contacts

Public ContactRupak Sett

Chittaranjan National Cancer Institute

debarshil@gmail.com9051513564

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026